GLP-1s are famous for their effectiveness, infamous for their price, and remain an enigma for those deciding if and how to provide coverage of these medications for their covered populations. Omada Health is back for another webinar, where we will answer questions you’ve raised around risks and side effects, best practices for managing the economic impact of adoption, and the future of these drugs for the millions of individuals who may clinically qualify for them.
Listen in on Carolyn Jasik, MD, Chief Medical Officer of Omada Health and Sara Kim, MD, Professor of Medicine at UCSF, as they answer the following questions:
What is the data on the short- and long-term outcomes, side effects, and risks for GLP-1s prescribed for the treatment and management of obesity?
Are there best practices to inform who should receive these medications, and how benefits providers should approach coverage?
GLP-1s have disrupted our approach to weight loss management. What’s next?
What is the role of evidence-based behavior modification programs for significant and sustainable weight loss in the presence of GLP-1s?
Carolyn Jasik, MD
Chief Medical Officer, Omada Health
Carolyn is a board-certified physician with a career spanning health technology startups, multidisciplinary care, education, and research associateships. As Omada’s Chief Medical Officer, she leverages her versatile skill set to benefit user experience and introduce patients and providers to integrated healthcare solutions. Before joining Omada, Carolyn spent 14 years with the University of California as an Associate Professor of Pediatrics and Clinical Instructor at San Francisco General Hospital. She’s also the former Vice President of medical outcomes for Mango Health, a digital health startup. She completed her Bachelor’s Degree in public policy from Princeton University’s Woodrow Wilson School, her Medical Degree at the University of Chicago’s Pritzker School of Medicine, and her research training at the University of California, San Francisco. Carolyn is board-certified in clinical informatics, adolescent medicine, and pediatrics. At Omada, Carolyn supports the clinical and research teams to create and test the next generation of integrated chronic disease care programming via digital therapeutics. Her work comprises an invaluable component of Omada’s stellar user experience benefiting patients and providers alike.
Sarah Kim, MD
Professor of Medicine, UCSF
ZSFG Division of Endocrinology, Diabetes and Metabolism
Sarah Kim, MD is a clinician educator with a particular interest in diabetes and obesity. Boarded in Adult Endocrinology as well as General Pediatrics, her clinic work has focused on Adult Diabetes as well as Adult and Pediatric Obesity. She works mainly at Zuckerberg San Francisco General Hospital caring for the San Francisco Safety Net Population. She also directs the UCSF Diabetes Teaching Center where they focus on diabetes educational programs. She participates in research activities, co-investigating studies that pertain to diabetes (ex., Metagenomics in Filipinos with Diabetes and the effect of Ketogenic Diet in Type 2 Diabetes). She enjoys a multitude of teaching activities that range from the School of Medicine, School of Nursing, UCSF Residents and Fellows.